Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...

A new agreement with OneTwo Analytics AB will allow Glucotrack to leverage next-generation artificial intelligence and machine learning-based analytics to evaluate clinical study data from its continu ...

Glucotrack, Inc. announced that it will present safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system at the 2025 International ...

Glucotrack (Nasdaq:GCTK) announced that it expects FDA investigational device exemption for its long-term CBGM later this ...

Glucotrack (GCTK) announced an agreement with OneTwo Analytics AB. Through this collaboration, Glucotrack will leverage next-generation ...

The Glucotrack Continuous Blood Glucose Monitor is an Investigational Device and is limited by federal (or United States) law to investigational use. For more information about Glucotrack’s CBGM ...

Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetesRUTHERFORD, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE ...

By integrating our expertise in clinical study analysis with Glucotrack’s groundbreaking glucose monitoring technology, we are poised to deliver a truly end-to-end solution for both healthcare ...